Clinical Trial Update: A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

Phase 2 study of etavopivat for anemia in patients with very low to intermediate risk myelodysplastic syndromes was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Etavopivat (Etavopivat)

Snippet

Sponsor: Forma Therapeutics, Inc. | Conditions: Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R | Phase 2 | Status: TERMINATED | Results posted: 2025-10-22